Phase IB/II of CPX-351 for Relapse Prevention in AML

This study tests a chemotherapy drug called CPX-351 to help prevent acute myeloid leukemia (AML — a cancer of the blood) from coming back in patients who have achieved remission but are not able to undergo a bone marrow transplant. **You may be eligible if...** - You are 18 or older with newly diagnosed AML that is now in complete remission - You received standard induction treatment and up to 6 cycles of consolidation therapy - You are not a candidate for a bone marrow transplant - Your heart function is adequate (ejection fraction at least 50%) - Your liver and kidney function are within acceptable ranges - You can start treatment within 3 months of your last documented remission **You may NOT be eligible if...** - You have had a prior bone marrow transplant - You have received high cumulative doses of certain heart-affecting chemotherapy drugs in the past - You have acute promyelocytic leukemia (a specific AML subtype) - You have active heart problems, Wilson's disease, or a copper metabolism disorder - You are pregnant or breastfeeding - You have active hepatitis B or C Talk to your doctor to see if this trial is right for you.